MRD Clinical Portfolio
Pipeline
Measure MRD
EARLY
DEVELOPMENT
AV/CV
CLIA/FDA
COMMERCIALIZED
ALL
EARLY
DEVELOPMENT
AV/CV
CLIA/FDA
COMMERCIALIZED
Bone Marrow
Blood
CLL
EARLY
DEVELOPMENT
AV/CV
CLIA/FDA
COMMERCIALIZED
Bone Marrow
Blood
MM
EARLY
DEVELOPMENT
AV/CV
CLIA/FDA
COMMERCIALIZED
Bone Marrow
Blood
NHL1
EARLY
DEVELOPMENT
AV/CV
CLIA/FDA
COMMERCIALIZED
cfDNA (DLBCL)
Blood
1 Available to order as a CLIA-validated laboratory developed test (LDT) service. This use has not been cleared or approved by the FDA.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT). For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary